Switzerland

Contact Us

Operations Center
Philip Morris International Management SA
Operations Center
Avenue de Rhodanie 50
1007 Lausanne
Switzerland

Tel : +41 (0)58 242 0000

Swiss Affiliate
Philip Morris SA
Chemin de Brillancourt 4
1001 Lausanne
Switzerland

Tel : +41 (0)58 242 0000
Quality Line : +41 (0)800 000 707

Research & Development
Philip Morris International Research & Development
Quai Jeanrenaud 5
2000 Neuchatel
Switzerland

Tel : + 41 (0)58 242 2111

Manufacturing Facility
Philip Morris Products SA
Quai Jeanrenaud 3
2000 Neuchâtel
Switzerland

Tel : +41 (0)32 888 62 11

Careers

GS Conference Technician

Switzerland
February 03, 2012

Medical Writer / Scientific Editor

Switzerland
February 03, 2012

Procurement Executive Electronics R&D - NGP

Switzerland
February 03, 2012

GS MAINTENANCE AUTOMATION TECHNICIAN

Switzerland
February 02, 2012

International Opportunities

Country Overview

Key Facts

Number of Employees: Approximately 3,000

Main Brands:
Marlboro, Philip Morris, Muratti, Brunette, Chesterfield, L&M

Philip Morris International (PMI) has a significant presence in Switzerland, employing approximately 3,000 people. Our history in Switzerland dates back to 1957 when we signed an agreement with the Neuchâtel-based Fabriques de Tabac Réunies, to produce the first Marlboro cigarettes manufactured outside the United States. In 1963, PMI acquired Fabriques de Tabac Réunies and today this factory is one of PMI’s most important manufacturing facilities, employing over 800 people. The factory produces cigarettes for both the domestic Swiss market and for export to over 40 countries around the world.

Philip Morris S.A., based in Lausanne, is responsible for sales and marketing activities in Switzerland. PM S.A. is the number one tobacco company in Switzerland, and its product portfolio includes 5 out of the top 11 cigarette brands in the country.

The city of Lausanne is also home to PMI’s worldwide Operations Center, where over 1,500 people work to support our business across the more than 180 countries where we sell our products.

PMI’s center for Research & Development (R&D) is also located in Switzerland. Over 535 R&D employees focus on the development of products with the potential to reduce the risk of tobacco related diseases.

Philip Morris International and its affiliates in Switzerland have an active charitable contributions program throughout the country. We support organizations that provide assistance in the communities where our employees live and work. Areas of focus include domestic violence prevention, anti-hunger programs, food banks, and counseling services.

Smoking and Health

Tobacco products, including cigarettes, are dangerous and addictive. There is overwhelming medical and scientific evidence that smoking causes lung cancer, heart disease, emphysema, and other serious diseases.

Addiction

All tobacco products are addictive. It can be very difficult to quit smoking, but this should not deter smokers who want to quit from trying to do so.

Secondhand Smoke
Public health officials have concluded that secondhand smoke from cigarettes causes serious diseases in non-smokers, including lung cancer and heart disease. We believe the public health conclusions on secondhand smoke are sufficient to support smoking restrictions in public places.

Effective Regulation
Philip Morris International (PMI) supports comprehensive regulation of tobacco products based on the principle of harm reduction.

To be effective, tobacco regulatory policy must be evidence-based, apply to all tobacco products, and should take into account the views of all legitimate stakeholders including public health authorities, government finance authorities, tobacco manufacturers, and other members of the tobacco supply chain. Regulatory policy must consider the potential to trigger adverse consequences which undermine public health objectives, such as increasing the demand for illicit cigarettes.

While we support comprehensive, effective tobacco regulation, we do not support regulation that prevents adults from buying and using tobacco products or that imposes unnecessary impediments to the operation of the legitimate tobacco market. In that regard, we oppose measures such as generic packaging, point of sale display bans, total bans on communications to adult consumers, and bans on the use of all ingredients in tobacco products.